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BACKGROUND: To describe the prescription patterns of analgesics during the last 3 months of life in lung cancer and to determine the
associated factors.
METHODS: Data on lung cancer patients (N¼10202) who died during 2000–2008 were extracted from the General Practice
Research Database (GPRD). This database records prescriptions of patients received from UK general practices (GP), but not those
from non-GP routes. Prescription prevalences were estimated. The associated factors were investigated using log-binomial
regression.
RESULTS: The overall prescription prevalences were 50.4% (95% confidence interval (CI): 49.4–51.4%) for level 1 (e.g., paracetamol),
34.1% (95% CI: 33.2–35.0%) for level 2 (weak opioids), and 55.5 % (95% CI: 54.5–56.4%) for level 3 analgesics (strong opioids).
Prescription prevalence of analgesics of all levels showed an increasing trend over the period 2000–2008 (annual increases range:
1.1–1.5%) but a decreasing trend with age (average decrease per group range:  5.8 to  1.8%). Patients in the older age groups
were less likely to be prescribed level 3 analgesics than those in the younger age groups (PR‘90þ’ vs ‘o50’¼0.55 (95% CI: 0.45–0.67);
PR‘80 89’ vs ‘o50’¼0.73 (95% CI: 0.66–0.79); PR‘70 79’ vs ‘o50’¼0.84 (95% CI: 0.77–0.90)).
CONCLUSION: Analgesics have been increasingly prescribed in lung cancer. However, analgesics, especially at level 3, were relatively
under-prescribed to people older than 70 years, warranting further investigation.
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Lung cancer is the leading cause of death from cancer, responsible
for over 1.4 million deaths worldwide and around 30000 deaths in
the United Kingdom each year (ONS, 2009; WHO, 2009). The
worldwide projected deaths from lung cancer will rise up to nearly
2.3 million in 2030 (WHO, 2009). Over 70% of lung cancer patients die
within a year after diagnosis (Rachet et al, 2009), leaving short time for
care planning. Pain is one of the most common and most feared
symptoms experienced by lung cancer patients. It affects 27% of
outpatients and 76% of patients cared for by palliative care services,
and significantly reduces quality of life (Di et al, 2004; Potter and
Higginson, 2004; Costantini et al, 2009). Its prevalence increases in
advanced disease. As death approaches, pain intensity increases
(Morris et al, 1986). Therefore, good control of pain has been regarded
as one of the primary goals of cancer care (Riley and Ross, 2005).
Pain may be related to the presence of primary or metastatic
disease; it may also develop because of treatment. An under-
standing of the mechanism of the pain may be helpful in planning
for optimal therapy (Levy, 1996; Bruera and Kim, 2003). The
majority (80%) of cancer pains can be controlled with simple
treatment. For the more complicated cases (20%), it is important
to use a multidimensional approach that includes a careful
re-assessment of the pain syndrome and use of second line agents
and/or non-pharmacological interventions (Zech et al, 1995).
For example, anti-hyperalgesic medications need to be considered
earlier on in the prescribing process for the neuropathic pain
(Ripamonti and Dickerson, 2001).
A three-step analgesic ladder has been proposed by the World
Health Organization (WHO) for managing cancer pain (WHO,
1996). It includes five core principles for the management of pain:
by the mouth (i.e., simple rather than invasive routes), by the clock
(i.e., regularly rather than only as required), for the individual,
with attention to detail and by the ladder (Jadad and Browman,
1995). This five-core principle is a stepwise approach to pain
management. The first step involves using non-opioids analgesics
for mild-to-moderate pain. Patients who fail the first-step regimen
or who present with moderate-to-severe pain should be treated
with weak opioids (step 2). For severe pain that cannot be
controlled by step 2, treatment should proceed to stronger opioids
(step 3). A systematic review found that 69–100% of patients
received adequate analgesia when the guidelines were applied
(Jadad and Browman, 1995).
However, recent surveys and meta-analysis of the available
empirical evidence show that the undertreatment of cancer pain
remains a widespread problem (Di et al, 2004; Deandrea et al,
2008). The inadequacy of analgesic treatment is even more
apparent in the advanced stage of disease. An Italian survey
conducted in patients with advanced non-small-cell lung cancer
revealed that as high as 82% of those who reported pain received
inadequate relief (Di et al, 2004).
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care practitioners, is the key to providing quality end of life care
and to enable more people approaching the end of their life to live
and die in their preferred place, usually at home (Gomes and
Higginson, 2006). The UK General Practice Research Database
(GPRD) is the world’s largest primary care database. The database
holds full records for over 4 million currently registered patients
and B11 million patients in total. These data are collected
from around 520 primary care practices throughout the
United Kingdom and cover 7% of the UK population. It contains
patient-level longitudinal medical records in primary care and has
the capacity to link to the other national databases. It has been
widely used for a variety of research areas including pharmacoe-
pidemiology, health service planning, and treatment patterns
(GPRD, 2010).
The objectives of this study are to determine the prescription
patterns of analgesics in the last year of life among patients with
lung cancer, and factors associated with these patterns.
MATERIALS AND METHODS
Design
This is a population-based observational study.
Data sources
The data for this study were extracted from the UK GPRD
database. All lung cancer patients who have at least one record
with one of the GPRD up-to-standard (UTS) practices, and who
died during the study period (from 1 January 2000 to 31 December
2008) were included for analysis. The diagnosis of lung cancer was
defined by Read/OXMIS codes. The Read/OXMIS codes used in
this study are available upon request from authors. The UTS
practices are those that contain at least 95% of all morbidity and
prescribing information in the regular data audit (Walley and
Mantgani, 1997). Pseudo-anonymised patients’ data on demo-
graphics, medical diagnoses, clinical consultations, analgesics
prescription information, history of smoking and alcohol drinking
status, referral and death information were recorded. Acquisition
of access to the database for this study was funded by the UK
Medical Research Council. The scientific and ethics advisory group
of the GPRD approved the study. As anonymised electronic
records were used as the source of data, written informed consent
was not required.
Outcome variable
(1) The prescription prevalence, defined as the proportion of
patients who received a certain category of analgesics
(according to the WHO three-step analgesic ladder) during a
defined time period compared with all patients with lung
cancer during the same time period;
(2) The binary indicator for whether a patient receives (status¼1)
analgesic prescription or not (status¼0).
We investigated the prescription prevalence and binary status
during the following three periods: last 1 to 3 months, last 3 to 6
months, and last 6 to 12 months. We examined level 1 (BNF code:
0407010; drugs including aspirin, paracetamol, non-steroidal
anti-inflammatory analgesics, NSAIDs), level 2 (BNF code:
0407020; drugs including codeine, tramadol, and dihydrocodeine),
and level 3 analgesics (BNF code: 0407020; drugs including
morphine, diamorphine, fentanyl, and alfentanyl, buprenorphine,
oxycodone, hydromorphone, methadone, pethidine, and meper-
idine). If patients received prescriptions of several levels of
analgesics at the same time, they were counted at the highest level.
Explanatory variables
Explanatory variables included age at diagnosis, gender, smoking
status, year of death, social economic status, and regions. The first
five were individual-level variables and the last two were practice-
level variables. Age at diagnosis was the difference between the
year of the first definite diagnostic code of lung cancer and the
patient’s year of birth. Age was grouped into seven groups (o30,
30–39, 40–49, 50–59, 60–69, 70–79, 80–89, 90þ years).
Smoking status was recorded in the GPRD database as ‘current
smoker’, ‘ex-smoker or unknown’, and ‘never smoker’. We
classified a person as a ‘current smoker’ if their smoking status
remained ‘current smoker’ across his/her whole consultation
history. Similarly, ‘never smoker’ was the one whose smoking
status remained being ‘never smoked’. All others or no consulta-
tion record of smoking status were categorised as ‘ex-smoker or
unknown’. The date of death was determined using the procedure
recommended by the GPRD. Year of death were in 1-year intervals
from 2000 to 2008. The social economic status (SES) is a practice-
level variable. It is calculated using the Index of Multiple
Deprivation (IMD). It was expressed using the quintile with the
lowest rank (0), indicating the least deprived, and the highest rank
(4), indicating the most deprived. The region in the GPRD
database was the NHS region in which the practice is based.
Statistical analysis
The prescription prevalence and their 95% confidence intervals
(95% CIs) were estimated. 95% CIs were constructed using normal
approximation methods. The w
2-test was used to test whether
proportions were significantly different between groups. The
trends for proportions of patients receiving analgesics were
estimated by the year of death, the age group, and the number
of weeks before death.
To investigate what factors associate with whether a patient
received a particular level of analgesics, we fitted the data with the
log-binomial regression model. The dependent variable was a
binary indicator of being prescribed a certain group of analgesics.
Correlations within general practices (GP) were accounted for by
using the generalised estimation equation method (Zeger et al,
1988). The working correlation matrix was specified as the
exchangeable type. Adjusted proportion ratios (PRs) and their
95% CIs were estimated from the log-binomial models. The
adjusted variables included age at diagnosis, gender, smoking
status, year of death, SES, and region. We tested both main effects
and interactions between independent factors. Since the GPRD
database records only prescriptions that patients received from the
general practitioners, it may miss prescriptions through non-GP
routes. Therefore, we conducted a sensitivity analysis by repeating
the main analysis using 3079 patients without referral records to
any inpatient services within the last 18 months of life, to assess
how the results might be affected by missed prescriptions.
All tests of statistical significance were two sided. We conducted
analyses using SAS statistical software, version 9.1.3 (SAS Institute,
Inc., Cary, NC, USA).
RESULTS
In total 10202 patients died of lung cancer during the study period.
Table 1 presents demographics of this population. 58.9% of the
patients were diagnosed after the age of 70. The ratio of female-to-
male lung cancer patients in this sample was 1:1.6 (39 vs 61%).
Around one in three (29.3%) were current smokers and 13.0%
were recorded as having never smoked. In the study sample, 28.2%
(n¼2880) of the patients were from GP in deprived areas (IMD
score¼4). The study population was widely spread across
the UK.
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levels of analgesics were 50.4% (95% CI: 49.4–51.4%) for level 1,
34.1% (95% CI: 33.2–35.0%) for level 2, and 55.5% (95% CI: 54.5–
56.4%) for level 3. Prescription prevalences were significantly
different by age, year of death, and region (Po0.05). But the
differences were not significant for the comparisons between those
with higher or lower social economic status for level 3 analgesics
(P¼0.39).
Prescription prevalence of any levels of analgesics in the last
3 months showed a small but significant increasing trend over the
years (Figure 1). The annual increases were, respectively, 1.2%
(95% CI: 0.8–1.6%, P¼0.001), 1.1% (95% CI: 0.8–1.5%,
Po0.001), and 1.5% (95% CI: 1.1–2.0%, P¼0.0002) for level 1,
level 2, and level 3 drugs. Level 3 analgesics prescription increased
from 47.2% (95% CI: 43.7–50.7%) in 2000 to 62.4% (95% CI: 59.7–
65.2%) in 2008. Over the period 2000–2008, around 50% of
patients received level 1 or level 3 analgesic prescriptions, o40%
of the patients had been prescribed level 2 analgesics. Prescriptions
of level 3 analgesics were slightly lower than those of level 1, but
experienced a dip from 2003 to 2004 and then sharper increase
since 2005.
Prescription prevalence for all three levels of analgesics
exhibited a linear and significant decreasing trend with increasing
age (level 1:  1.8% (95% CI:  2.5 to  1.2%, P¼0.005); level
2:  2.6% (95% CI:  3.2 to  1.9%, P¼0.002); level 3:  5.8% (95%
CI:  7.6 to  4.1%, P¼0.003) (Figure 2). Analgesic prescriptions
of level 1 (range: 45.8–55.1%) and level 3 (range: 36.0–65.0%)
were both higher in all age groups than level 2 (range:
26.2–39.9%). Prescription prevalence of level 3 drugs were higher
than those of level 1 in younger age groups (o70 years) but started
dropping from the ‘70–79’ age group to lower than level 1 in the
‘90þ’ group.
People without any analgesics prescriptions in the last 3 months
presented a downward trend by year of death ( 1.4%; 95% CI:
 1.8 to  1.0%; Po0.001) and an upward trend by age group
(2.9%; 95% CI: 2.2–3.6%; P¼0.001), the mirror-reflection images
of prescription prevalence of analgesics, particularly for level
3 analgesics (Figures 1 and 2).
Log-binomial regression analysis (Table 2) showed that age is a
significant predictor for a patient receiving analgesics prescrip-
tions in the last 3 months of life. The chance of a patient being
prescribed analgesics was negatively associated with age. The
chance starts dropping from the ‘70–79’ age group; the lowest level
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Figure 1 Time trend of prescription prevalence (95% CI) of level 1, level 2,
and level 3 analgesics (according to the WHO analgesic ladder) in patients
with lung cancer and proportion of patients without analgesic prescriptions
during the last 3 months of life, 2000–2008 (n¼10202). Annual change:
level 1: 1.2% (95% CI: 0.8–1.6%, P¼0.001); level 2: 1.1% (95% CI: 0.8–
1.5%, Po0.001); level 3: 1.5% (95% CI: 1.1–2.0%, Po0.0001); No
prescription:  1.4% (95% CI:  1.8 to  1.0%; Po0.001).
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Figure 2 Prescription prevalence (95% CI) of level 1, level 2, and level 3
analgesics (according to the WHO analgesic ladder) in patients with lung
cancer and proportion of patients without analgesic prescriptions by age
groups (n¼10202). Average change per age group: level 1:  1.8% (95%
CI:  2.5 to  1.2%, P¼0.005); level 2:  2.6% (95% CI:  3.2 to  1.9%,
P¼0.002); level 3:  5.8% (95% CI:  7.6 to  4.1%, P¼0.003);
No prescription: 2.9% (95% CI: 2.2–3.6%; P¼0.001).
Table 1 Demographics of lung cancer patients who died between
1 January 2000 and 31 December 2008 in the General Practice Research
Database (GPRD)
Variable N (%)
All groups 10202
Age at diagnosis (years)
o50 383 (3.8)
50–59 1145 (11.2)
60–69 2661 (26.1)
70–79 3759 (36.9)
80–89 2029 (19.9)
90+ 225 (2.2)
Gender
Female 3982 (39.0)
Male 6220 (61.0)
Smoking
Never 1325 (13.0)
Current 2992 (29.3)
Ex-smoker or unknown 5886 (57.7)
Year of death
2000 790 (7.7)
2001 952 (9.3)
2002 998 (9.8)
2003 1045 (10.2)
2004 1229 (12.1)
2005 1290 (12.6)
2006 1321 (13.0)
2007 1400 (13.7)
2008 1177 (11.5)
Social-economic status (SES)
0 (Least deprived) 1747 (17.1)
1 1720 (16.9)
2 1871 (18.3)
3 1984 (19.5)
4 (Most deprived) 2880 (28.2)
Region
Eastern 1335 (13.1)
London 959 (9.4)
North East 897 (8.8)
North West and West Midland 2688 (26.4)
Northern Ireland 282 (2.8)
Scotland 715 (7.0)
Southern 2692 (26.4)
Wales 634 (6.2)
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are less likely to receive a level 3 (PR: 0.55; 95% CI: 0.45–0.67),
level 2 (PR: 0.66; 95% CI: 0.52–0.85), or level 1 (PR: 0.80; 95% CI:
0.67–0.96) analgesic prescription than those diagnosed before the
age of 50 years, respectively. Females had a slightly higher chance
to receive level 3 (PR: 1.06; 95% CI: 1.02–1.10) analgesics than
males. There was no gender difference in level 1 (PR: 0.99; 95%
CI: 0.95–1.02) or level 2 analgesic prescriptions (PR: 1.05; 95%
CI: 0.99–1.10).
Never-smokers were less likely than smokers to be prescribed
level 2 analgesics (PR: 0.90; 95% CI: 0.82–1.00), but no difference
in receiving the other levels of analgesic prescriptions. After
adjusting for the effects of all other predictors, the annual
increasing trend was still significant for all levels of analgesics.
Patients registered with practices in least deprived regions had a
slightly lower chance (P40.05) of receiving any levels of analgesics
than in most deprived regions in the last 3 months, with the PRs
ranging from 0.93 to 0.99. There are significant regional differences
in prescribing analgesics. Patients in London had the least chance
to get a prescription of any level of analgesics. Those in the
Southern region had the highest chance of being prescribed level 3
analgesics. We did not find significant interaction effects between
independent variables.
Results of sensitivity analysis (Appendix Table A1) were
generally consistent with our main findings but fewer factors
reached a significant level, probably due to smaller sample size.
DISCUSSION
Our analysis showed an increasing trend of prescribing level 3
analgesics (strong opioids) in UK primary care. This is consistent
with a Norwegian study using a national prescription database
(Fredheim et al, 2010). In the last 3 months, patients receiving level
3 analgesic prescriptions increased from one in two (47.2%) in
2000 to two in three (62.4%) in 2008. By 2008, two in three patients
had been prescribed in the last 3 months of life level 1 (52.8%) and
level 3 (62.4%) analgesics, and nearly one in two level 2 analgesics
(36.4%). The increasing prescribing trend of analgesics towards
end of life was similar to that found in a smaller Dutch survey of
Table 2 Prevalence ratios (PRs)
a of factors associated with a patient receiving three levels of analgesic prescriptions during the last 3 months
of life (n¼10202)
Level 1 Level 2 Level 3
Variable PR (95% CI) P PR (95% CI) P PR (95% CI) P
Age (years)
o50 1.00 o0.001 1.00 o0.001 1.00 o0.001
50–59 0.93 (0.83–1.03) 0.89 (0.77–1.03) 1.02 (0.93–1.10)
60–69 0.94 (0.85–1.04) 0.90 (0.79–1.03) 0.94 (0.87–1.02)
70–79 0.89 (0.81–0.98) 0.82 (0.72–0.93) 0.84 (0.77–0.90)
80–89 0.82 (0.73–0.91) 0.74 (0.65–0.85) 0.73 (0.66–0.79)
90+ 0.80 (0.67–0.96) 0.66 (0.52–0.85) 0.55 (0.45–0.67)
Gender
Male 1.00 0.46 1.00 0.09 1.00 0.002
Female 0.99 (0.95–1.02) 1.05 (0.99–1.10) 1.06 (1.02–1.10)
Smoking status
Smoker 1.00 0.006 1.00 0.12 1.00 0.27
Ex-smoker or unknown 1.07 (1.03–1.12) 0.99 (0.93–1.05) 1.03 (0.99–1.07)
Never smoker 1.05 (0.98–1.13) 0.90 (0.82–1.00) 0.99 (0.93–1.05)
Year of death
2000 1.00 o0.001 1.00 o0.001 1.00 o0.001
2001 1.03 (0.92–1.15) 1.03 (0.89–1.21) 1.10 (0.99–1.21)
2002 1.14 (1.03–1.25) 1.14 (0.98–1.32) 1.19 (1.08–1.31)
2003 1.08 (0.97–1.20) 1.10 (0.95–1.26) 1.15 (1.05–1.27)
2004 1.15 (1.04–1.26) 1.14 (1.00–1.31) 1.14 (1.03–1.26)
2005 1.19 (1.08–1.31) 1.27 (1.11–1.45) 1.22 (1.11–1.34)
2006 1.18 (1.07–1.29) 1.25 (1.09–1.43) 1.20 (1.09–1.32)
2007 1.22 (1.12–1.34) 1.32 (1.17–1.50) 1.27 (1.15–1.40)
2008 1.19 (1.08–1.31) 1.26 (1.10–1.43) 1.34 (1.22–1.47)
Socio-economic status (SES)
0 (Least deprived) 1.00 0.31 1.00 0.35 1.00 0.27
1 0.97 (0.90–1.06) 1.04 (0.94–1.14) 0.99 (0.93–1.07)
2 1.03 (0.96–1.11) 1.06 (0.95–1.18) 1.02 (0.95–1.09)
3 1.03 (0.96–1.10) 0.99 (0.90–1.10) 1.04 (0.97–1.12)
4 (Most deprived) 1.05 (0.98–1.12) 1.08 (0.98–1.19) 1.06 (0.99–1.13)
Region
Wales 1.00 0.38 1.00 o0.001 1.00 0.002
Eastern 0.99 (0.90–1.10) 0.87 (0.77–0.99) 1.06 (0.95–1.18)
London 0.99 (0.90–1.10) 0.87 (0.77–0.99) 1.06 (0.95–1.18)
North East 0.96 (0.86–1.08) 0.79 (0.69–0.90) 1.01 (0.90–1.14)
North West and West Midlands 1.06 (0.95–1.18) 0.99 (0.86–1.14) 1.13 (1.01–1.27)
Northern Ireland 1.04 (0.94–1.14) 0.95 (0.85–1.08) 1.10 (0.99–1.21)
Scotland 1.03 (0.90–1.17) 1.18 (1.02–1.37) 1.12 (0.97–1.31)
Southern 1.06 (0.95–1.19) 1.01 (0.87–1.18) 1.14 (1.02–1.28)
Abbreviation: CI¼confidence interval.
aPRs were estimated using log-binomial regression model, the listed variables in the table were including in the model as the
independent variables.
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this pattern may well be replicated in other countries.
Interestingly, between 2003 and 2004 there was a small dip in
analgesic prescribing in primary care. At around this time, the case
of Harold Shipman (the doctor who murdered patients using
opioids) was dramatised and made known to professionals and the
wider public. There have been some concerns that this case would
adversely affect appropriate opioid prescribing and pain manage-
ment (Baker et al, 2004). We find a small amount of evidence to
support a small dip in prescribing – the effect was short term
though, and the upward trend in opioid prescribing continued.
However, this finding highlights the need for continued education
in opioids, and the prevalent use in the last 3 months of life
suggests that community services need to be trained in the
administration, including out of hours. This may be important in
ensuring support at home (Gomes and Higginson, 2006).
However, we found older age being significantly and indepen-
dently associated with lower prescriptions of any levels of
analgesics in primary care. Though analgesic prescribing is a
balance of benefits vs harms, and this balance can sometimes be
difficult to achieve, mounting evidence in the other settings
consistently suggested pain management is more problematic for
older people (Cleeland et al, 1994; Bernabei et al, 1998; Closs et al,
2009; Oldenmenger et al, 2009). Reasons why older people are
apparently undertreated for pain are likely to be multifaceted: (1) it
may be that older people are less likely to report pain; (2) they may
have atypical manifestations of pain; (3) there may be patients’
misconceptions about tolerance and addiction to opioids; (4) there
may be co-morbidities that limit treatments; or (5) the needs of
older people with lung cancer may be missed (Oldenmenger et al,
2009). It is known that specialist palliative care services have
seemed to focus on younger patients, rather than those in older age
groups (Eve and Higginson, 2000; Lock and Higginson, 2005) and
much of the opioid prescriptions may be prompted by palliative
care teams. Therefore, it is likely that older people with lung cancer
and pain are not receiving optimal treatment. Adequate assess-
ment of pain is key to effective management (Oldenmenger et al,
2009), but this will require better integration of pain assessment
into busy clinical practices.
Gender differences in pain and analgesia have been increasingly
reported in basic research as well as in clinical settings: women are
more sensitive to pain but less responsive to analgesic treatment
than men (Fillingim and Gear, 2004; Potter and Higginson, 2004;
Gaumond et al, 2007). This may explain why female patients in our
study exhibited a slightly higher chance of receiving analgesic
prescriptions in the last year of life. The mechanisms behind the
phenomenon may be attributed to multiple factors, from genes and
reproductive hormones to socio-cultural and environmental
factors (Mogil, 1999; Craft et al, 2004; Greenspan et al, 2007;
Nielsen et al, 2008), all may play a part.
Smoking is a well-recognised risk factor for lung cancer,
accounting for around 85–90% of cases (Cancer Research UK,
2009). An American study found that persistent smoking after a
diagnosis of lung cancer is associated with higher pain levels
(Daniel et al, 2009). Another study of 112 newly diagnosed head
and neck cancer patients also observed that current smokers
reported higher general and oral pain levels than did never and
former smokers (Logan et al, 2009). Our findings do not support
these observations – in our study only level 2 analgesics were
slightly lower in non-smokers (30.0 vs 35.1%). The main difference
between our study and the earlier work is that we focused on the last
3 months of a patient’s life. Whether the effects of smoking on pain
wane at the end of life and subsequently influence the chance of a
patient getting analgesic prescriptions would need further study.
A review of published data found socio-economical variables
being the strongest determinant for undertreatment (Deandrea
et al, 2008). Our results suggest a tendency for patients from
deprived backgrounds receiving more analgesic prescriptions from
their GPs. However, the difference is not statistically significant.
We are not able to exclude the possibility of undertreatment of pain,
but the reimbursement policy in the United Kingdom may be of
help in reducing any inequality in pain relief (Cherny et al, 2010).
This study revealed an interesting finding in regional differences
in analgesics prescriptions. Despite London having a relatively high
density of palliative services (as do the South East and North West
regions), prescribing rates are low. A possible reason might be the
imbalance in service provision. A national survey for palliative care
service provision across the United Kingdom found that London has
the lowest level of day care places, though the other service
categories rank high (National Council for Hospice and Specialist
Palliative Care Services, 2000). Scientific evidence suggests that
palliative day care service is associated with improved pain and
symptom control (Goodwin et al, 2003); our results also highlight
the importance of enhancing palliative day care service.
Several limitations of our study need to be recognised. First,
since the GPRD database only record analgesics prescribed by GPs,
we may miss some analgesic prescriptions that patients received
through non-GP routes; therefore, the prescriptions reported here
were generally underestimated. This is particularly true for level
1 and level 2 analgesics, which patients can buy directly at a
pharmacy without a prescription. It may have been used especially
by patients from higher socio-economic backgrounds. Equally,
some level 3 analgesics may have been provided by hospitals, and
we do not know what analgesics were prescribed once patients
entered hospitals or hospices, which may be the likely situation
during the last several weeks of a patient’s life. Furthermore,
prescriptions are normally written for a 3-month duration, so in
the later months patients may be using their earlier drugs (possibly
at increased dose) without needing another prescription. The issue
is more of a problem in the later part of the end of life journey than
in the early. However, the sensitivity analysis showed such
underestimation does not have major impact on our main results.
Second, restricted by data availability, we could not evaluate
analgesic prescriptions in relation to actual pain prevalence and
intensity. Pain was under-recorded in primary care. In the last
3 months, only 16.3% (1668 out of 10202) of the patients had pain
recorded in their clinical histories, in contrast to an overall 55.5% of
patients having been prescribed level 3 analgesics. Effective cancer
pain management relies heavily on accurate assessment of the nature
and severity of the patient’s pain. We did not have this information
since pain assessment is not routinely performed and recorded in
most settings including primary care (Oldenmenger et al, 2009);
however, we would like to emphasise the need for education and
training of clinicians on the value of documenting pain assessments,
on appropriate use of medications guided by the WHO analgesic
principle, on monitoring any adverse effects and on maintaining
communication with patients and families (Bruera and Kim, 2003).
Third, the factors we could adjust for in multiple regression
analysis were limited. For example, ‘ethnic group’ may be one of
the influencing factors for optimal pain management, but we do
not have this information. Finally, it should be noted that some
prescriptions at level 3 would include level 2 or level 1 drugs.
However, this does not invalidate our findings, as it would
represent appropriate treatment.
In conclusion, we found an increasing trend in UK general
practitioners prescribing all levels of analgesics in the last 3 months
of lung cancer patients. However, people older than 70 years of age
were relatively under-prescribed for all levels of analgesics,
particularly at level 3; therefore, warranting further investigation
and suggesting attention to the needs of older lung cancer patients.
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Table A1 Prevalence ratios (PRs)
a of factors associated with a patient receiving three levels of analgesic prescriptions during the last 3 months of life,
based on patients without referral records to any of inpatient services (n¼3072)
Level 1 Level 2 Level 3
Variable PR (95% CI) P PR (95% CI) P PR (95% CI) P
Age (years)
o50 1.00 0.010 1.00 0.002 1.00 o0.001
50–59 0.86 (0.72–1.02) 0.89 (0.69–1.16) 0.96 (0.83–1.11)
60–69 0.86 (0.74–1.00) 0.95 (0.75–1.20) 0.90 (0.78–1.03)
70–79 0.84 (0.72–0.97) 0.79 (0.62–0.99) 0.83 (0.73–0.94)
80–89 0.72 (0.61–0.85) 0.73 (0.57–0.93) 0.68 (0.58–0.80)
90+ 0.80 (0.61–1.04) 0.66 (0.43–1.03) 0.61 (0.43–0.85)
Gender
Male 1.00 0.22 1.00 0.53 1.00 0.74
Female 0.96 (0.89–1.03) 1.03 (0.94–1.13) 1.01 (0.95–1.07)
Smoking status
Smoker 1.00 0.66 1.00 0.12 1.00 0.41
Ex-smoker or unknown 1.03 (0.95–1.11) 0.98 (0.88–1.09) 0.95 (0.89–1.02)
Never smoker 1.05 (0.93–1.18) 0.83 (0.68–1.01) 0.96 (0.87–1.07)
Year of death
2000 1.00 0.035 1.00 0.13 1.00 0.022
2001 1.02 (0.82–1.27) 1.00 (0.76–1.31) 0.97 (0.81–1.16)
2002 1.06 (0.89–1.27) 1.03 (0.78–1.37) 1.06 (0.91–1.23)
2003 1.05 (0.86–1.29) 0.92 (0.71–1.20) 0.98 (0.83–1.16)
2004 1.10 (0.92–1.33) 1.02 (0.79–1.31) 1.00 (0.85–1.19)
2005 1.25 (1.04–1.51) 1.15 (0.89–1.48) 1.10 (0.93–1.30)
2006 1.17 (0.97–1.40) 1.18 (0.92–1.51) 1.08 (0.92–1.26)
2007 1.17 (0.97–1.40) 1.21 (0.95–1.53) 1.12 (0.96–1.31)
2008 1.24 (1.04–1.47) 1.19 (0.95–1.49) 1.19 (1.02–1.39)
Socio-economic status (SES)
0 (Least deprived) 1.00 0.91 1.00 0.68 1.00 0.58
1 0.97 (0.86–1.10) 0.99 (0.85–1.15) 0.95 (0.85–1.05)
2 1.03 (0.92–1.15) 0.97 (0.82–1.16) 0.98 (0.90–1.07)
3 0.98 (0.88–1.09) 0.89 (0.75–1.06) 1.00 (0.91–1.09)
4 (Most deprived) 1.02 (0.91–1.13) 1.00 (0.84–1.17) 1.04 (0.95–1.13)
Region
Wales 1.00 0.10 1.00 0.19 1.00 0.020
Eastern 1.04 (0.86–1.24) 0.91 (0.75–1.12) 1.10 (0.94–1.28)
London 1.17 (0.97–1.41) 0.86 (0.69–1.07) 1.13 (0.98–1.30)
North East 1.12 (0.93–1.35) 1.10 (0.87–1.38) 1.33 (1.14–1.56)
North West and West Midlands 1.08 (0.91–1.27) 0.95 (0.78–1.15) 1.22 (1.07–1.39)
Northern Ireland 0.96 (0.74–1.23) 1.10 (0.79–1.53) 1.18 (0.98–1.41)
Scotland 1.17 (0.96–1.42) 1.00 (0.76–1.32) 1.28 (1.10–1.50)
Southern 0.98 (0.83–1.16) 0.84 (0.69–1.02) 1.23 (1.08–1.41)
Abbreviation: CI¼confidence interval.
aPRs were estimated using log-binomial regression model, the listed variables in the table were including in the model as the independent
variables.
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